Case Report

Dedifferentiated Liposarcoma of the Retroperitoneum with Extensive Leiomyosarcomatous Differentiation and β -Human Chorionic Gonadotropin Production

Michael J. Russell,^{1,2} Frederick L. Flynt,³ Allyson L. Harroff,⁴ and Oluwole Fadare^{1,5}

¹ Department of Pathology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA

² Pathology Program, San Antonio Uniformed Services Health Education Consortium, San Antonio, TX 78236, USA

³ Department of Internal Medicine, Wilford Hall Medical Center, Lackland Air Force Base, TX 78236, USA

⁴ Department of Hematology/Oncology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA

⁵ Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

Correspondence should be addressed to Oluwole Fadare, oluwolefadare@yahoo.com

Received 20 August 2007; Revised 4 November 2007; Accepted 12 February 2008

Recommended by Cyril Fisher

Dedifferentiated liposarcomas may display a variety of "heterologous" lines of differentiation, including osseous, vascular, skeletal, and/or smooth muscular. There have been six previously reported examples of leiomyosarcomas associated with high levels of serum human chorionic gonadotropin (hCG) production, comprised of cases originating from the retroperitoneum, spermatic cord, small intestine, and uterus. This report describes the first example of a dedifferentiated liposarcoma that combined both of the aforementioned features: extensive heterologous (leiomyosarcomatous) differentiation *and* β -hCG production (maximum serum levels 1046 mIU/ml, reference < 5 mIU/ml). The tumor, which originated in the retroperitoneum in the region of the right kidney, was rapidly progressive and ultimately fatal within three months of its diagnosis. In addition to characteristic morphologic features, lipogenic and smooth muscle differentiation were confirmed with immunohistochemical stains for MDM2 and smooth muscle actin, respectively. The tumor also displayed diffuse immunoreactivity for β -hCG in both primary and metastatic sites. This case further expands the clinicopathologic spectrum of lipogenic tumors.

Copyright © 2008 Michael J. Russell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

The term "tumor dedifferentiation" and its underlying concepts, as used by contemporary surgical pathologists, are based on the paradigm originally outlined by Dahlin and Beabout in low-grade chondrosarcomas [1]. Tumor dedifferentiation is characterized by the "emergence" of an undifferentiated component (phenotypically unrecognizable as to histogenesis) from an otherwise low-grade/borderline neoplasm, with well-defined morphologic demarcations between the aforementioned areas and a relatively worsened clinical course. The phenomenon of tumor dedifferentiation has subsequently been described in a wide variety of bone, soft tissue, and epithelial and neural neoplasms [2].

Tumor dedifferentiation is probably most well characterized in lipogenic tumors. Although it had been previously noted that well-differentiated and pleomorphic sarcomas may be admixed [3, 4], dedifferentiated liposarcoma (DDLS) was formally described by Evans in 1979 [5]. In a series of 55 liposarcomas, 8 cases (7 retroperitoneal, 1 spermatic cord) were noted to display "distinct areas of well-differentiated liposarcoma and of cellular spindle cell or pleomorphic sarcoma without recognizable lipogenesis" [5]. None of the latter cases displayed a mitotic count of >5/10 high power fields, and the cellular areas were often sharply demarcated from the well-differentiated areas [5]. Subsequent reports indicated that (a) dedifferentiation in well-DDLS is probably not anatomic site specific but time dependent [6], (b) most retroperitoneal tumors previously classified as malignant fibrous histiocytomas are actually DDLS [7], (c) most examples of DDLS present as de novo lesions rather than as a complication of a preexisting well-differentiated liposarcoma [8], (d) DDLS may be classified into high and low grade depending on mitotic activity and cellularity, although the prognostic significance of this gradation is unclear [8–11].

As with their clinical spectrum, the pathologic spectrum of DDLS has been similarly expanded. Newer morphologic observations have included a potentially poorly defined interface between the DDLS and its well-differentiated component [8], whorled, meningothelial-like structures [8, 12–14], a prominent inflammatory component [9], a micronodular growth pattern [9], a hemangiopericytomatous vascular pattern [8, 9], and heterologous differentiation [8, 9, 14–20].

Chondroid metaplasia, rhabdomyosarcomatous, and smooth muscular differentiation have been described in welldifferentiated and myxoid liposarcomas [2, 21–24]; the term *lipoleiomyosarcoma* is commonly used for morphologic admixtures of well-differentiated liposarcoma and leiomyosarcoma. [23]. However, the probability for histologic misclassification is highest when high-grade DDLS displays heterologous differentiation [4, 5, 8, 9, 11–16]. Lines of heterologous differentiation that have been described in DDLS include leiomyosarcomatous, osteochondrosarcomatous, angiosarcomatous, and rhabdomyosarcomatous and do not appear to have independent prognostic significance [4, 5, 8, 9, 11–16, 25]

This report describes an example of a retroperitoneal DDLS with extensive leiomyosarcomatous differentiation that was accompanied by high levels of serum beta-human chorionic gonadotropin (β -hCG). This composite of findings has, to our knowledge, not been previously reported.

2. CLINICAL HISTORY

In 2006, a 67-year-old Caucasian female presented with episodic right upper quadrant abdominal pain and associated nausea. Her past medical history was significant for an infiltrating ductal breast carcinoma (treated with radical mastectomy followed by 4 cycles of adriamycin in 1999), a stable plasma cell dyscrasia (multiple myeloma diagnosed by a bone marrow biopsy and serum protein electrophoresis in 2003, treated with high dose chemotherapy, and which was associated with a mild normocytic anemia in the ensuing period), and a hysterectomy/salpingo-oophorectomy (for benign indications). A computed tomographic (CT) scan of the abdomen showed a heterogeneously enhancing mass extending from the inferior right renal pole exophytically, with significant associated inflammatory changes and some peripheral coarse calcifications. Portocaval and mesenteric adenopathy were also present. Serum levels of alphafetoprotein, carcinoembryonic antigen, CA15-3, and CA27-29 were within normal limits. Notably, a serum β -hCG, requested inadvertently, measured 210.3 mIU/ml (reference value for nongestational adults <5 mIU/L).

Given the high suspicion for a renal cell carcinoma, the right kidney was resected as well as all grossly identifiable perinephric tumor. Intraoperatively, the mass was noted to be prominently adhered to the surrounding retroperitoneal tissue. A follow-up serum β -hCG, which was measured 26 days after the first measurement and 25 days after her surgical procedure, measured 1046 mIU/ml. An abdominal CT scan performed shortly thereafter revealed multiple hypo-

dense liver masses measuring up to 5 cm, with an increase in the aforementioned portocaval adenopathy. Biopsy of one of the hepatic masses confirmed the presence of metastatic disease. The patient declined further therapeutic measures and expired 2 months later. An autopsy was not performed.

3. MATERIALS AND METHODS

Twenty sections of the retroperitoneal mass were routinely processed for microscopic evaluation. The liver biopsy was similarly processed. For immunohistochemistry, $4-5 \mu$ -thick sections were cut and mounted on a glass slide, deparaffinized and rehydrated. Appropriate negative and positive controls were included. All assays were carried out in an Axiom 36 autostainer (Lab Vision Corporation, Fremont, Calif, USA). The following markers were evaluated in the liver biopsy and a representative section of the retroperitoneal mass, in parallel: β -hCG (clone CG04+CG05, prediluted, Lab Vision), keratin cocktail comprised of clones AE1/AE3 (Signet Corporation, Dedham, Mass, USA) and LP34 (DakoCytomation, Carpinteria, Calif, USA), dilution 1:200, Smooth muscle actin: SMA (clone1A4, prediluted, Lab Vision), Estrogen receptor-alpha: ER-alpha (clone ID5, dilution 1:50, DakoCytomation), Progesterone receptor: PR (clone PgR 636, prediluted, DakoCytomation), Desmin (clone D33, prediluted, Lab Vision), Epithelial membrane antigen (EMA) (clone E29, prediluted, ThermoFisher Scientific, Fremont, Calif, USA), MDM2 (clone IF2, dilution 1:100, Lab Vision), and placental-like alkaline phosphatase: PLAP (Clone SP15, prediluted, Lab Vision).

4. PATHOLOGIC FEATURES

4.1. Macroscopic

The kidney and associated perinephric tissue measured in aggregate $21 \times 10 \times 7$ cm. Sectioning revealed an inferior pole mass measuring 9.5 cm in maximum dimension, which compressed and distorted the renal pelvis and the tissue in this region. The cut surface of the mass was largely firm and solid, tan-white in color, with hemorrhagic areas but no grossly identifiable necrosis.

4.2. Morphologic features

The retroperitoneal tumor displayed the characteristic morphologic features of DDLS. In the well-differentiated component, large coarse fibrotic bands were observed irregularly, coursing through lobules of well-differentiated adipocytes. Within the fibrous bands, the perivascular regions and within the adipocytic lobules were scattered cells with large irregular and hyperchromatic nuclei (Figure 1). The mitotic index in these regions was low. The dedifferentiated component comprised approximately 80% of the tumor mass. The interface between the well-differentiated and dedifferentiated components was variable: the interface was well demarcated in some regions (Figure 2), and highly irregular/infiltrative in others. The central portion of the mass was necrotic, while the surrounding areas, comprising approximately 10% of the mass were hypocellular and hyalinized. However, atypical



FIGURE 1: Well-differentiated component of the liposarcoma, showing atypical cells with nucleomegaly and hyperchromasia scattered within mature adipocytes and intervening fibrous septae.



FIGURE 2: The interface between the well-differentiated and dedifferentiated components.



FIGURE 3: Cellular areas of the dedifferentiated component.

cells well still recognizable in these regions. The remainder of the mass displayed a spectrum of pathologic changes with respect to cellularity, mitotic activity and atypia. Nonetheless, the tumor was predominantly a high-grade pleomorphic spindle cell sarcoma. In the most hypocellular regions, scattered atypical cells were clearly evident in a hyalinized background and displayed a maximum mitotic index of 11 MF/10 high power fields. Other areas were significantly more cel-



FIGURE 4: Some areas of the dedifferentiated component were comprised of cells with varying amounts of eosinophilic cytoplasm.

lular, and were comprised of cells with hyperchromatic nuclei arranged in vague fascicles (Figure 3). These areas displayed the highest mitotic activity (maximum 36 MF/10 high power fields). Constituent cell displayed variable amounts of eosinophilic cytoplasm (Figure 4). The growth pattern of the tumor relative to the adjacent kidney was largely to displace it. However, there were areas where the tumor appeared to infiltrate in an interstitial pattern, with glomeruli encircled by tumor cells. The portions of the tumor not comprised of spindle cells were comprised of nondescript pleomorphic cells. Lipoblasts were evident throughout the tumor and there were no morphologically-recognizable syncytiotrophoblasts. The portion of the liver mass that was sampled was comprised predominantly of spindle cells as described above.

4.3. Immunophenotypic features

The retroperitoneal tumor and liver mass displayed an identical immunoprofile, consistent with the latter being a metastatic deposit from the former. Both displayed diffuse immunoreactivity for desmin, SMA, β -hCG (Figure 5), and MDM2 (Figure 6). The tumors were negative for ER, PR, EMA, PLAP, and keratins.

5. DISCUSSION

hCG, a glycoprotein with a molecular weight of 38 000, is comprised of two subunits— α and β —that are noncovalently bound to form a heterodimer [26, 27]. The α subunit of hCG is identical to the α subunits of luteining hormone, follicle stimulating hormone, and thyrotropin; the β subunit therefore provides hormonal specificity [26, 27]. The measurement of serum β -hCG has its greatest clinical utility in the diagnosis of gestation, congenital disorders, and germ cell neoplasia. However, it has long been recognized that a wide variety of other nongerm cell neoplasms, predominantly carcinomas, may be associated with elevated serum β -hCG, in which it appears to function as an autocrine growth factor by inhibiting apoptosis [28, 29]. The expression of hCG has also been found to be an adverse prognostic factor in some specific histotypes such as small cell lung carcinoma,



FIGURE 5: The tumor cells displayed diffuse immunoreactivity for β -hCG.



FIGURE 6: The tumor cells displayed diffuse immunoreactivity for MDM2.

transitional cell carcinoma of the urinary bladder, and prostatic and colorectal adenocarcinoma [30–33]. Rare examples of osteosarcoma [28, 34–36], chondrosarcoma [37], and leiomyosarcoma [38–43] have been associated with elevated serum β -hCG. Amongst the six previously reported examples of β -hCG-producing leiomyosarcomas, two originated in the retroperitoneum [42, 43], two in the spermatic cord [39, 41], one in the uterus [40], and one in the small intestine [38]. Notably, five of the six patients succumbed to their disease within one year of their diagnoses. However, the sarcomas were high grade; thus the independent prognostic significance of β -hCG remains unclear.

In the present case, a DDLS with extensive leiomyosarcomatous differentiation was associated with β -hCG production, as evidenced by demonstration of β -hCG expression in the tumor and its metastatic deposit by immunohistochemistry, and an elevation of serum β -hCG that was temporally related to tumor progression. The diagnostic utility of MDM2, a recently described marker reportedly useful for distinguishing DDLS from their histologic mimics [44], was confirmed, as this marker helped to establish, in addition to morphologic features, underlying lipogenic differentiation.

 β -hCG production by DDLS has not been previously reported to our knowledge and is presumed to represent "aberrant" differentiation in a high-grade tumor. Nonetheless, this finding expands the clinicopathologic spectrum of lipogenic

tumors in general. Furthermore, it suggests that liposarcoma should be a differential consideration when elevated serum β -hCG is associated with a radiographic mass lesion, especially when the mass is retroperitoneal.

REFERENCES

- D. C. Dahlin and J. W. Beabout, "Dedifferentiation of lowgrade chondrosarcomas," *Cancer*, vol. 28, no. 2, pp. 461–466, 1971.
- [2] J. Rosai, "Current concepts of dedifferentiation in soft tissue and bone sarcomas," in *Proceedings of the Annual Meeting of the International Society of Bone and Soft Tissue Pathology*, San Antonio, Tex, USA, February-March 2005.
- [3] F. M. Enzinger and D. J. Winslow, "Liposarcoma: a study of 103 cases," Virchows Archiv, vol. 335, no. 4, pp. 367–388, 1962.
- [4] L. G. Kindblom, L. Angervall, and P. Svendsen, "Liposarcoma a clinicopathologic, radiographic and prognostic study," *Acta Pathologica et Microbiologica Scandinavica*, no. 253, pp. 1–71, 1975.
- [5] H. L. Evans, "Liposarcoma: a study of 55 cases with a reassessment of its classification," *The American Journal of Surgical Pathology*, vol. 3, no. 6, pp. 507–523, 1979.
- [6] S. W. Weiss and V. K. Rao, "Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites: a follow-up study of 92 cases with analysis of the incidence of "dedifferentiation"," *The American Journal of Surgical Pathology*, vol. 16, no. 11, pp. 1051–1058, 1992.
- [7] J.-M. Coindre, O. Mariani, F. Chibon, et al., "Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma," *Modern Pathol*ogy, vol. 16, no. 3, pp. 256–262, 2003.
- [8] W. H. Henricks, Y. C. Chu, J. R. Goldblum, and S. W. Weiss, "Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation," *The American Journal of Surgical Pathology*, vol. 21, no. 3, pp. 271–281, 1997.
- [9] D. McCormick, T. Mentzel, A. Beham, and C. D. M. Fletcher, "Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas," *The American Journal of Surgical Pathol*ogy, vol. 18, no. 12, pp. 1213–1223, 1994.
- [10] F. Elgar and J. R. Goldblum, "Well-differentiated liposarcoma of the retroperitoneum: a clinicopathologic analysis of 20 cases, with particular attention to the extent of low-grade dedifferentiation," *Modern Pathology*, vol. 10, no. 2, pp. 113–120, 1997.
- [11] H. L. Evans, "Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum followup of 10 years," *The American Journal of Surgical Pathology*, vol. 31, no. 1, pp. 1–14, 2007.
- [12] C. Kuhnen, T. Mentzel, R. Sciot, M. Lehnhardt, H.-H. Homann, and M. Debiec-Rychter, "Dedifferentiated liposarcoma with extensive lymphoid component," *Pathology Research and Practice*, vol. 201, no. 4, pp. 347–353, 2005.
- [13] J. C. Fanburg-Smith and M. Miettinen, "Liposarcoma with meningothelial-like whorls: a study of 17 cases of a distinctive histological pattern associated with dedifferentiated liposarcoma," *Histopathology*, vol. 33, no. 5, pp. 414–424, 1998.
- [14] A. G. Nascimento, P. J. Kurtin, L. Guillou, and C. D. M. Fletcher, "Dedifferentiated liposarcoma: a report of nine cases with a peculiar neurallike whorling pattern associated with

metaplastic bone formation," *The American Journal of Surgical Pathology*, vol. 22, no. 8, pp. 945–955, 1998.

- [15] R. P. Salzano Jr., Z. Tomkiewicz, and W. A. Africano, "Dedifferentiated liposarcoma with features of rhabdomyosarcoma," *Connecticut Medicine*, vol. 55, no. 4, pp. 200–202, 1991.
- [16] H. L. Evans, K. K. Khurana, B. L. Kemp, and A. G. Ayala, "Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma," *The American Journal of Surgical Pathology*, vol. 18, no. 11, pp. 1150–1157, 1994.
- [17] G. Tallini, R. A. Erlandson, M. F. Brennan, and J. M. Woodruff, "Divergent myosarcomatous differentiation in retroperitoneal liposarcoma," *The American Journal of Surgical Pathology*, vol. 17, no. 6, pp. 546–556, 1993.
- [18] T. Hasegawa, K. Seki, F. Hasegawa, et al., "Dedifferentiated liposarcoma of retroperitoneum and mesentery: varied growth patterns and histological grades—a clinicopathologic study of 32 cases," *Human Pathology*, vol. 31, no. 6, pp. 717–727, 2000.
- [19] S. Shimada, T. Ishizawa, K. Ishizawa, K. Kamada, and T. Hirose, "Dedifferentiated liposarcoma with rhabdomyoblastic differentiation," *Virchows Archiv*, vol. 447, no. 5, pp. 835–841, 2005.
- [20] S. Pilotti, A. Mezzelani, B. Vergani, et al., "Morphologiccytogenetic analysis of dedifferentiated liposarcomas with an extensive misleading leiomyosarcomatous component," *Applied Immunohistochemistry and Molecular Morphology*, vol. 8, no. 3, pp. 216–221, 2000.
- [21] H. L. Evans, "Smooth muscle in atypical lipomatous tumors. A report of three cases," *The American Journal of Surgical Pathol*ogy, vol. 14, no. 8, pp. 714–718, 1990.
- [22] S. Suster, T.-Y. Wong, and C. A. Moran, "Sarcomas with combined features of liposarcoma and leiomyosarcoma: study of two cases of an unusual soft-tissue tumor showing dual lineage differentiation," *The American Journal of Surgical Pathol*ogy, vol. 17, no. 9, pp. 905–911, 1993.
- [23] A. L. Folpe and S. W. Weiss, "Lipoleiomyosarcoma (welldifferentiated liposarcoma with leiomyosarcomatous differentiation): a clinicopathologic study of nine cases including one with dedifferentiation," *The American Journal of Surgical Pathology*, vol. 26, no. 6, pp. 742–749, 2002.
- [24] D. Govender and P. Pillay, "Primary myxoid liposarcoma with rhabdomyoblastic differentiation," *Archives of Pathology and Laboratory Medicine*, vol. 122, no. 8, pp. 740–742, 1998.
- [25] M. B. N. Binh, L. Guillou, I. Hostein, et al., "Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas," *The American Journal of Surgical Pathology*, vol. 31, no. 10, pp. 1557–1566, 2007.
- [26] V. C. Stevens, "Human chorionic gonadotrophin: properties and potential immunological manipulation for clinical application," *Clinics in Obstetrics and Gynaecology*, vol. 6, no. 3, pp. 549–566, 1979.
- [27] A. J. Lapthorn, D. C. Harris, A. Littlejohn, et al., "Crystal structure of human chorionic gonadotropin," *Nature*, vol. 369, no. 6480, pp. 455–461, 1994.
- [28] S. Gailani, T. M. Chu, A. Nussbaum, M. Ostrander, and N. Christoff, "Human chorionic gonadotrophins (hCG) in nontrophoblastic neoplasms. Assessment of abnormalities of hCG and CEA in bronchogenic and digestive neoplasms," Cancer, vol. 38, no. 4, pp. 1684–1686, 1976.
- [29] R. K. Iles, "Ectopic hCGβ expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis," *Molecular and Cellular Endocrinology*, vol. 260– 262, pp. 264–270, 2007.

- [30] M. T. Sheaff, J. E. Martin, D. F. Badenoch, and S. I. Baithun, "βhCG as a prognostic marker in adenocarcinoma of the prostate," *Journal of Clinical Pathology*, vol. 49, no. 4, pp. 329– 332, 1996.
- [31] A. Kido, M. Mori, Y. Adachi, H. Yukaya, T. Ishida, and K. Sugimachi, "Immunohistochemical expression of β-human chorionic gonadotropin in colorectal carcinoma," *Surgery Today*, vol. 26, no. 12, pp. 966–970, 1996.
- [32] M. Szturmowicz, E. Wiatr, A. Sakowicz, et al., "The role of human chorionic gonadotropin β subunit elevation in small-cell lung cancer patients," *Journal of Cancer Research and Clinical Oncology*, vol. 121, no. 5, pp. 309–312, 1995.
- [33] G. Moutzouris, D. Yannopoulos, C. Barbatis, A. Zaharof, and C. Theodorou, "Is β-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy?" *British Journal of Urology*, vol. 72, no. 6, pp. 907–909, 1993.
- [34] N. G. Ordonez, A. G. Ayala, A. K. Raymond, C. Plager, R. S. Benjamin, and N. A. Samaan, "Ectopic production of the βsubunit of human chorionic gonadotropin in osteosarcoma," *Archives of Pathology and Laboratory Medicine*, vol. 113, no. 4, pp. 416–419, 1989.
- [35] J. K. Kalra, R. Mir, L. B. Kahn, Z. Wessely, and A. B. Shah, "Osteogenic sarcoma producing human chorionic gonadotrophin. Case report with immunohistochemical studies," *Cancer*, vol. 53, no. 10, pp. 2125–2128, 1984.
- [36] B. Leidinger, S. Bielack, G. Koehler, V. Vieth, W. Winkelmann, and G. Gosheger, "High level of β-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literature," *Journal of Cancer Research and Clinical Oncology*, vol. 130, no. 6, pp. 357–361, 2004.
- [37] G. R. Mack, D. B. Robey, and R. J. Kurman, "Chondrosarcoma secreting chorionic gonadotropin: report of a case," *Journal of Bone and Joint Surgery*, vol. 59, no. 8, pp. 1107–1111, 1977.
- [38] R. F. Meredith, L. D. Wagman, J. A. Piper, A. S. Mills, and J. P. Neifeld, "β-chain human chorionic gonadotropin-producing leiomyosarcoma of the small intestine," *Cancer*, vol. 58, no. 1, pp. 131–135, 1986.
- [39] C. Seidl, C. Lippert, V. Grouls, and W. Jellinghaus, "Leiomyosarcoma of the spermatic cord with paraneoplastic β-hCG production," *Pathologe*, vol. 19, no. 2, pp. 146–150, 1998.
- [40] S. Liang, G. Stone, E. Chalas, M. Pearl, F. Callan, and W. Zheng, "A high-grade uterine leiomyosarcoma with human chorionic gonadotropin production," *International Journal of Gynecological Pathology*, vol. 25, no. 3, pp. 257–261, 2006.
- [41] S.-M. Ou, S.-S. Lee, Y.-J. Peng, L.-F. Sheu, N.-S. Yao, and S.-Y. Chang, "Production of β-hCG by spermatic cord leiomyosarcoma: a paraneoplastic syndrome?" *Journal of Andrology*, vol. 27, no. 5, pp. 643–644, 2006.
- [42] I. A. Mansi, I. Ashley, and V. Glezerov, "Retroperitoneal leiomyosarcoma and enlarged epididymis associated with a positive pregnancy test," *The American Journal of the Medical Sciences*, vol. 324, no. 2, pp. 104–105, 2002.
- [43] M. P. Froehner, H.-J. Gaertner, A. Manseck, S. Oehlschlaeger, and M. P. Wirth, "Retroperitoneal leiomyosarcoma associated with an elevated β-hCG serum level mimicking extragonadal germ cell tumor," *Sarcoma*, vol. 4, no. 4, pp. 179–181, 2000.
- [44] M. B. N. Binh, X. Sastre-Garau, L. Guillou, et al., "MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data," *The American Journal of Surgical Pathology*, vol. 29, no. 10, pp. 1340–1347, 2005.



The Scientific **World Journal**



Gastroenterology Research and Practice





Journal of Diabetes Research



Disease Markers



Immunology Research





Submit your manuscripts at http://www.hindawi.com





BioMed **Research International**



Journal of Ophthalmology

Computational and Mathematical Methods in Medicine





Behavioural Neurology









Research and Treatment





Oxidative Medicine and Cellular Longevity



Stem Cells International

